CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the e...
Saved in:
| Main Authors: | E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-12-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1196 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
by: E. S. Kuvardin, et al.
Published: (2022-11-01) -
PHARMACOKINETIC RESEARCHES AND PRACTICAL MEDICINE
by: V. G. Belolipetskaya, et al.
Published: (2015-12-01) -
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01) -
Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. A. Akimova, et al.
Published: (2023-03-01) -
Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)